As of 2026-03-14, the EV/EBITDA ratio of Enorama Pharma AB (ERMA.ST) is -1.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ERMA.ST's latest enterprise value is 51.67 mil SEK. ERMA.ST's TTM EBITDA according to its financial statements is -44.88 mil SEK. Dividing these 2 quantities gives us the above ERMA.ST EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 3.1x - 5.6x | 4.2x |
| Forward P/E multiples | 5.1x - 6.6x | 5.3x |
| Fair Price | (1.41) - 46.60 | 17.80 |
| Upside | -326.1% - 7391.2% | 2761.8% |
| Date | EV/EBITDA |
| 2026-03-12 | -0.89 |
| 2026-03-11 | -1.15 |
| 2026-03-10 | -1.37 |
| 2026-03-09 | -1.46 |
| 2026-03-06 | -1.26 |
| 2026-03-05 | -1.39 |
| 2026-03-04 | -1.21 |
| 2026-03-03 | -1.38 |
| 2026-03-02 | -1.25 |
| 2026-02-27 | -1.44 |
| 2026-02-26 | -1.62 |
| 2026-02-25 | -1.63 |
| 2026-02-24 | -1.18 |
| 2026-02-23 | -1.38 |
| 2026-02-20 | -1.41 |
| 2026-02-19 | -1.20 |
| 2026-02-18 | -1.89 |
| 2026-02-17 | -1.51 |
| 2026-02-16 | -1.96 |
| 2026-02-13 | -2.04 |
| 2026-02-12 | -2.88 |
| 2026-02-11 | -3.53 |
| 2026-02-10 | -2.68 |
| 2026-02-09 | -2.97 |
| 2026-02-06 | -1.86 |
| 2026-02-05 | -1.11 |
| 2026-02-04 | -1.44 |
| 2026-02-03 | -1.76 |
| 2026-02-02 | -3.02 |
| 2026-01-30 | -3.07 |
| 2026-01-29 | -3.01 |
| 2026-01-28 | -3.05 |
| 2026-01-27 | -3.08 |
| 2026-01-26 | -3.06 |
| 2026-01-23 | -2.95 |
| 2026-01-22 | -3.05 |
| 2026-01-21 | -2.99 |
| 2026-01-20 | -3.14 |
| 2026-01-19 | -3.25 |
| 2026-01-15 | -3.50 |
| 2026-01-14 | -3.50 |
| 2026-01-13 | -3.34 |
| 2026-01-12 | -3.59 |
| 2026-01-09 | -3.63 |
| 2026-01-08 | -3.99 |
| 2026-01-07 | -4.05 |
| 2026-01-05 | -4.05 |
| 2026-01-02 | -3.99 |
| 2025-12-30 | -3.84 |
| 2025-12-29 | -4.44 |